Orchestra BioMed (OBIO) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Orchestra BioMed (OBIO) has outperformed Vanda Pharmaceuticals (VNDA) over the past year, gaining 97.6% versus a loss of 17.0%. Over five years, OBIO leads with a -41.8% price change compared with -75.4% for VNDA. Orchestra BioMed is the larger company by market cap ($343.8 million vs $273.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OBIO | VNDA |
|---|---|---|
| Share price | $5.72 | $4.53 |
| Market cap | $343.80M | $273.90M |
| 1-day change | -0.17% | 0.00% |
| YTD return | +38.07% | -48.64% |
| 1-year return | +97.59% | -17.03% |
| 5-year return | -41.83% | -75.39% |
| Forward P/E | — | 22.65 |
| EPS (TTM) | $-0.86 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.50 | $9.94 |
| 52-week low | $2.86 | $4.27 |
| Distance from 52-week high | -12.00% | -54.43% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +117.31% | +159.38% |
| Average volume | 299.84K | 974.13K |
| Shares outstanding | 60.11M | 60.46M |
| Employees | 86 | 533 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OBIO has outperformed VNDA by 114.6 percentage points over the past year.
About Orchestra BioMed
OBIO stock →Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Health Care · Medicinal Chemicals and Botanical Products · 86 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
OBIO vs VNDA FAQ
Which is bigger, Orchestra BioMed or Vanda Pharmaceuticals?
Orchestra BioMed (OBIO) is larger, with a market capitalization of $343.80M compared with $273.90M for Vanda Pharmaceuticals (VNDA).
Which stock has performed better over the past year, OBIO or VNDA?
OBIO returned +97.59% over the past 12 months, compared with -17.03% for VNDA (price return, excluding dividends). Past performance does not predict future results.
Are Orchestra BioMed and Vanda Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Medicinal Chemicals and Botanical Products for Orchestra BioMed and Biotechnology: Pharmaceutical Preparations for Vanda Pharmaceuticals.